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increased use of prophylaxis. Few studies have analyzed
the total costs of treatment, hence we undertook this
study. METHODS: To determine total costs and trends
of treating children with severe hemophilia-A from 1978
to 1998, at the Hospital for Sick Children in Toronto, one
patient chart reviewer identiﬁed resource consumption of
all patients (n = 17). For each patient, costs for factor con-
centrate, clinic visits, physicians and healthcare profes-
sionals (physiotherapists/social workers), laboratory and
other tests (x-ray, MRI, ultrasound) and hospitalizations
were determined. Costs in Canadian dollars were taken
from standard lists and discounted at 3%. RESULTS:
Total average cost (range) was $69,322 ($14,471–
$108,294)/year/patient of which the largest part, $65,184
($8,250–$107,104), 94% (57%–99%) was accounted for
by Factor-VIII. Hospitalizations accounted for $2,396
($0–$57,063)/patient/year including drugs, nursing care
and stay. Clinic visits and physician visits were $1290
($122–$4143) and $177 ($0–$308), respectively. Health-
care professionals averaged $89 ($0–$252) and lab tests
and other tests cost $156 ($26–$226) and $31 ($4–
$70)/patient/year, respectively. The average number of
bleeds was 12.9 (2.0–22.0)/patient/year. Since 1978, the
average number of bleeds decreased by 0.71 (r2 = 0.56)/
patient/year. The average number of hospitalizations 
was 0.21 (0–4)/patient/year, in which patients stayed on
average 10.7 (1–135) days. Since 1984, the number of
hospitalizations has decreased by 0.5 hospitalizations/
patient/year (r2 = 0.74). Concurrently, the average costs
of the treatment of severe hemophiliacs have increased by
approximately $3740 (r2 = 0.62)/patient/year. Clotting
factor concentrate cost per patient increased by $4215 (r2
= 0.66)/year, of which prophylaxis accounted for $1429
(r2 = 0.60)/year, while on demand Factor-VIII costs
decreased by $497 (r2 = 0.16)/year. CONCLUSIONS:
The annual cost of hemophilia care, of $69,322 per
patient, is substantial. The number of bleeds and 
hospitalizations is decreasing while there was a clear
trend in increasing costs of treating severe hemophiliacs,
primarily associated with increasing use of prophylactic
treatment.
PPT6
HEMOPHILIA ECONOMIC MODEL OF
OUTCOMES: CASE STUDY
Evans C1, Roberts HR2, Sagrolikar A3, Gomperts E3,
Poulios N3
1Mapi Values, Boston, MA, USA; 2University of North Carolina,
Chapel Hill, NC, USA; 3Baxter Healthcare Corporation,
Westlake Village, CA, USA
OBJECTIVES: In Asia, individuals with hemophilia are
often treated with cryoprecipitate as it is considered a less
expensive option. However, the risk of acquiring blood-
borne infections is higher with cryoprecipitate than with
factor concentrates. Any acquisition cost savings that
occur with the use of cryoprecipitate may be offset by
greater total healthcare costs to treat transmissible
viruses. METHODS: A literature review was conducted
to obtain estimates of the prevalence of HIV, HBV and
HCV in the blood supply and costs of treating the sub-
sequent diseases. Data from international health organi-
zations, local experts in the treatment of hemophilia, and
the local Red Cross Society was utilized. This data forms
the basis of an economic and outcomes model for hemo-
philia treatment in this Asian country. RESULTS: Based
on the data identiﬁed, the risk of exposure to the blood-
borne infections in hemophiliacs treated with cryoprecip-
itate is substantial: 3%, 6% and 12% at 5, 10 and 20
years respectively for HIV. Risk for developing hepatitis
infection was higher. The discounted cost of treating 
the three infectious diseases is substantial. For patients
treated with cryoprecipitate total treatment costs were
$26,575 and $64,291.06 at 10 and 20 years. For patients
treated with factor concentrate equivalent costs were
$32,200 and $64,401. CONCLUSIONS: Over time, the
acquisition cost savings associated with cryoprecipitate
use, compared to factor concentrate, disappears as the
costs for treating transmissible viruses in infected patients
increases.
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OBJECTIVES: To investigate whether long-term growth
hormone (GH) replacement therapy in GH deﬁcient
(GHD) adults results in improvements in Quality of Life
(QoL), patient-reported outcomes and health care uti-
lization (HCU) in the Netherlands. METHODS: The
analysis was based on 74 patients (35 men, 39 women)
and all patients were included in KIMS (Pharmacia Inter-
national Metabolic Survey)—the largest pharmacoepi-
demiological survey of GHD adults on GH therapy. Data
were available for all patients for the ﬁrst year of treat-
ment, and 2-year follow-up data were available for 38
patients. QoL was assessed using the Nottingham Health
Proﬁle (NHP) and disease-speciﬁc AGHDA question-
naire. Patient reported outcomes and data on HCU were
obtained with the Patient Life Situation Form (PLSF). Sta-
tistical analyses were performed with repeated measure-
ments technique. RESULTS: Both QoL questionnaires
showed a signiﬁcant improvement after 1 and 2 years of
GH therapy (from 20.1 ± 2.6 to 10.1 ± 2.5 for NHP, from
9.3 ± 0.82 to 7.2 ± 1.11 for AGHDA). Data collected
